Forte Biosciences, Inc.
Clinical trials sponsored by Forte Biosciences, Inc., explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New drug aims to restore skin color in vitiligo patients Results expected Dec 2026 (estimated)
- New drug FB102 begins first human safety tests Results expected Feb 2027 (estimated)
- New biologic FB102 takes on celiac disease in Mid-Stage trial Results expected Feb 2027 (estimated)
- New drug hopes to regrow hair in severe alopecia Results expected Mar 2027 (estimated)
-
New drug aims to restore skin color in vitiligo patients
Disease control Recruiting nowThis early-stage trial tests a new drug called FB102 in 64 adults with non-segmental vitiligo, a condition that causes white patches on the skin. Half will get the drug and half a placebo, both given by IV. The main goal is to check safety and see if the drug helps bring back ski…
Phase 1 • Sponsor: Forte Biosciences, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:59 UTC
-
New drug hopes to regrow hair in severe alopecia
Disease control Recruiting nowThis early-stage trial tests a drug called FB102 in 32 adults with severe to very severe alopecia areata, a condition causing significant hair loss. Half receive the drug and half a placebo, all by IV. The main goal is to check safety, but researchers will also measure hair regro…
Phase 1 • Sponsor: Forte Biosciences, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
New biologic FB102 takes on celiac disease in Mid-Stage trial
Disease control Recruiting nowThis study tests a new biologic drug called FB102 in 100 adults with celiac disease who already follow a strict gluten-free diet. Participants will receive either FB102 or a placebo and then undergo a controlled gluten challenge to see if the drug can reduce intestinal damage and…
Phase 2 • Sponsor: Forte Biosciences, Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
New drug FB102 begins first human safety tests
Knowledge-focused Recruiting nowThis Phase 1 trial tests the safety and tolerability of a new drug called FB102 in 56 healthy volunteers. Participants receive either a single dose, multiple weekly doses, or a placebo. The study focuses on side effects and how the drug moves through the body, not on treating any…
Phase 1 • Sponsor: Forte Biosciences, Inc. • Aim: Knowledge-focused
Last updated Aug 21, 2026 00:00 UTC